Tidemark LLC Takes $123,000 Position in Hologic, Inc. (NASDAQ:HOLX)

Tidemark LLC purchased a new position in Hologic, Inc. (NASDAQ:HOLX) during the fourth quarter, Holdings Channel.com reports. The fund purchased 1,724 shares of the medical equipment provider’s stock, valued at approximately $123,000.

A number of other hedge funds also recently modified their holdings of HOLX. Victory Capital Management Inc. boosted its holdings in Hologic by 4.5% in the 4th quarter. Victory Capital Management Inc. now owns 5,055,048 shares of the medical equipment provider’s stock worth $361,183,000 after buying an additional 216,958 shares during the period. Norges Bank bought a new position in shares of Hologic in the fourth quarter worth $217,529,000. Hsbc Holdings PLC grew its position in shares of Hologic by 9.0% in the third quarter. Hsbc Holdings PLC now owns 1,721,339 shares of the medical equipment provider’s stock valued at $119,472,000 after purchasing an additional 141,542 shares in the last quarter. DekaBank Deutsche Girozentrale raised its stake in shares of Hologic by 2.9% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 1,634,362 shares of the medical equipment provider’s stock valued at $115,586,000 after purchasing an additional 45,785 shares during the period. Finally, Nordea Investment Management AB lifted its holdings in Hologic by 4.5% during the 3rd quarter. Nordea Investment Management AB now owns 1,616,999 shares of the medical equipment provider’s stock worth $113,077,000 after purchasing an additional 69,494 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Insider Activity

In related news, Director Charles J. Dockendorff sold 1,465 shares of Hologic stock in a transaction on Friday, March 8th. The shares were sold at an average price of $76.21, for a total value of $111,647.65. Following the transaction, the director now owns 1,572 shares in the company, valued at approximately $119,802.12. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, Director Charles J. Dockendorff sold 1,465 shares of the firm’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $76.21, for a total transaction of $111,647.65. Following the transaction, the director now directly owns 1,572 shares of the company’s stock, valued at $119,802.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Scott T. Garrett sold 16,441 shares of Hologic stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $75.50, for a total value of $1,241,295.50. Following the completion of the transaction, the director now owns 48,611 shares in the company, valued at approximately $3,670,130.50. The disclosure for this sale can be found here. 1.75% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

HOLX has been the subject of a number of recent analyst reports. StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 target price on shares of Hologic in a report on Friday, May 3rd. UBS Group raised their price target on shares of Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a report on Friday, February 2nd. Argus upped their price target on shares of Hologic from $89.00 to $95.00 and gave the stock a “buy” rating in a report on Thursday, May 9th. Finally, Evercore ISI boosted their target price on Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research report on Thursday, April 4th. Five research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $85.60.

Hologic Price Performance

Shares of HOLX traded down $0.68 during midday trading on Thursday, reaching $74.13. The stock had a trading volume of 310,157 shares, compared to its average volume of 1,684,543. The company has a current ratio of 3.97, a quick ratio of 3.29 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $17.30 billion, a price-to-earnings ratio of 38.17, a price-to-earnings-growth ratio of 2.48 and a beta of 1.01. The company’s 50-day moving average is $76.17 and its 200 day moving average is $73.81. Hologic, Inc. has a 12-month low of $64.02 and a 12-month high of $82.45.

Hologic (NASDAQ:HOLX) last released its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $0.98 by $0.05. Hologic had a return on equity of 18.91% and a net margin of 11.78%. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1 billion. During the same quarter in the previous year, the company posted $1.06 EPS. Hologic’s quarterly revenue was down .8% compared to the same quarter last year. On average, equities analysts predict that Hologic, Inc. will post 4.08 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.